Comparison of polymorphisms in genes involved in polycyclic aromatic hydrocarbon metabolism with urinary phenanthrene metabolite ratios in smokers

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 10, 2006, Pages 1805-1811

  Hecht, Stephen S ^a   Carmella, Steven G ^a   Yoder, Andrea ^a   Chen, Menglan ^a   Li, Zhong Ze ^a   Le, Chap ^a   Dayton, Rachel ^a   Jensen, Joni ^a   Hatsukami, Dorothy K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; PHENANTHRENE DERIVATIVE; PHENANTHROLINE DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON;

ADULT; ARTICLE; CANCER RISK; CARCINOGENICITY; CONTROLLED STUDY; DETOXIFICATION; DNA POLYMORPHISM; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; LUNG CANCER; MALE; METABOLIC ACTIVATION; PHENOTYPE; PRIORITY JOURNAL; SMOKING; URINALYSIS;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A1; EPOXIDE HYDROLASES; FEMALE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MINNESOTA; PHENANTHRENES; POLYCYCLIC HYDROCARBONS, AROMATIC; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 33748992714     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0173     Document Type: Article

References (77)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 83. Lyon (France): IARC; 2004. p. 1179-87.
3. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
4. Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA damage, and p53 mutations in smoking-associated cancers. Oncogene 2002;21:7435-51.
5. Hecht SS. Tobacco carcinogens, their biomarkers, and tobacco-induced cancer. Nat Rev Cancer 2003;3:733-44.
6. Straif K, Baan R, Grosse Y, et al. Carcinogenicity of polycyclic aromatic hydrocarbons. Lancet Oncol 2005;6:931-2.
7. Cooper CS, Grover PL, Sims P. The metabolism and activation of benzo[a]pyrene. Prog Drug Metab 1983;7:295-396.
8. Thakker DR, Yagi H, Levin W, et al. Polycyclic aromatic hydrocarbons: metabolic activation to ultimate carcinogens. In: Anders MW, editor. Bioactivation of foreign compounds. New York: Academic Press, Inc.; 1985. p. 177-242.
9. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92:1525-30.
10. Ross JA, Nesnow S. Polycyclic aromatic hydrocarbons: correlations between DNA adducts and ras oncogene mutations. Mutat Res 1999;424:155-66.
11. Harris CC, Autrup H, Connor R, et al. Interindividual variation in binding of benzo[a]pyrene to DNA in cultured human bronchi. Science 1976;194:1067-9.
12. Nebert DW. Drug-metabolizing enzymes, polymorphisms, and interindividual response to environmental toxicants. Clin Chem Lab Med 2000;38:857-61.
13. Alexandrov K, Cascorbi I, Rojas M, et al. CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis 2002;23:1969-77.
14. Sabadie N, Richter-Reichhelm HB, Saracci R, et al. Inter-individual differences in oxidative benzo(a)pyrene metabolism by normal and tumorous surgical lung specimens from 105 lung cancer patients. Int J Cancer 1981;27:417-25.
15. Nowak D, Schmidt-Preuss U, Jorres R, et al. Formation of DNA adducts and water-soluble metabolites of benzo[a]pyrene in human monocytes is genetically controlled. Int J Cancer 1988;41:169-73.
16. McLemore TL, Adelberg S, Liu MC, et al. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 1990;82:1333-9.
17. Kiyohara C, Nakanishi Y, Inutsuka S, et al. The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics 1998;8:315-23.
18. Houlston RS. CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. Pharmacogenetics 2000;10:105-14.
19. Bartsch H, Nair U, Risch A, et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000;9:3-28.
20. Benhamou S, Lee WJ, Alexandrie AK, et al. Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis 2002;23:1343-50.
21. Hung RJ, Boffetta P, Brockmoller J, et al. CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis 2003;24:875-82.
22. Le Marchand L, Guo C, Benhamou S, et al. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control 2003;14:339-46.
23. Vineis P, Veglia F, Benhamou S, et al. CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer 2003;104:650-7.
24. Lee WJ, Brennan P, Boffetta P, et al. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers 2002;7:230-41.
25. Taioli E, Pedotti P. Pooled analysis on metabolic gene polymorphisms and lung cancer. Exp Lung Res 2005;31:217-22.
26. Liu G, Zhou W, Christiani DC. Molecular epidemiology of non-small cell lung cancer. Semin Respir Crit Care Med 2005;26:265-72.
27. Vineis P, Veglia F, Anttila S, et al. CYP1A1, GSTM1, and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions. Biomarkers 2004;9:298-305.
28. Hecht SS, Chen M, Yagi H, et al. r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4- tetrahydrophenanthrene in human urine: a potential biomarker for assessing polycyclic aromatic hydrocarbon metabolic activation. Cancer Epidemiol Biomarkers Prev 2003;12:1501-8.
29. Carmella SG, Chen M, Yagi H, et al. Analysis of phenanthrols in human urine by gas chromatography-mass spectrometry: potential use in carcinogen metabolite phenotyping. Cancer Epidemiol Biomarkers Prev 2004;13:2167-74.
30. Hecht SS, Chen M, Yoder A, et al. Longitudinal study of urinary phenanthrene metabolite ratios: effect of smoking on the diol epoxide pathway. Cancer Epidemiol Biomarkers Prev 2005;14:2969-74.
31. Conney AH. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G.H.A. Clowes Memorial Lecture. Cancer Res 1982;42:4875-917.
32. Baird WM, Ralston SL. Carcinogenic polycyclic aromatic hydrocarbons. In: Bowden GT and Fischer SM, editors. Comprehensive toxicology: chemical carcinogens and anticarcinogens, vol. 12. New York: Elsevier Science Ltd.; 1997. p. 171-200.
33. Shou M, Korzekwa KR, Krausz KW, et al. Regio- and stereo-selective metabolism of phenanthrene by twelve cDNA-expressed human, rodent, and rabbit cytochromes P-450. Cancer Lett 1994;83:305-13.
34. Bauer E, Guo Z, Ueng YF, et al. Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem Res Toxicol 1995;8:136-42.
35. Shou M, Korzekwa KR, Crespi CL, et al. The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol. Mol Carcinogenesis 1994;10:159-68.
36. Kim JH, Stansbury KH, Walker NJ, et al. Metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis 1999;19:1847-53.
37. Shimada T, Gillam EMJ, Oda Y, et al. Metabolism of benzo[a]pyrene to trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase. Chem Res Toxicol 1999;12:623-9.
38. Shimada T, Hayse CL, Yamazaki H, et al. Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res 1996;56:2979-84.
39. Guenthner TM, Oesch F. Microsomal epoxide hydrolase and its role in polycyclic aromatic hydrocarbon biotransformation. In: Gelboin HV, Ts'o POP, editors. Polycyclic hydrocarbons and cancer, vol. 3. New York (NY): Academic Press; 1981. p. 183-212.
40. Sundberg K, Dreij K, Seidel A, et al. Glutathione conjugation and DNA adduct formation of dibenzo[a,l]pyrene and benzo[a]pyrene diol epoxides in V79 cells stably expressing different human glutathione transferases. Chem Res Toxicol 2002;15:170-9.
41. Sundberg K, Johansson AS, Stenberg G, et al. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis 1998;19:433-6.
42. Sundberg K, Widersten M, Seidel A, et al. Glutathione conjugation of bay- and fjord-region diol epoxides of polycyclic aromatic hydrocarbons by glutathione transferase M1-1 and P1-1. Chem Res Toxicol 1997;10:1221-7.
43. Robertson IGC, Guthenberg C, Mannervik B, et al. Differences in stereoselectivity and catalytic efficiency of three human glutathione transferases in the conjugation of glutathione with 7β,8α-dihyroxy- 9α,10α-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene. Cancer Res 1986;46:2220-4.
44. Hecht SS, Murphy SE, Carmella SG, et al. Effects of reduced cigarette smoking on uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst 2004;96:107-15.
45. Joseph AM, Hecht SS, Murphy SE, et al. Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. Cancer Epidemiol Biomarkers Prev 2005;14:2963-8.
46. Kokoris M, Dix K, Moynihan K, et al. High-throughput SNP genotyping with the Masscode system. Mol Diagn 2000;5:329-40.
47. Smith GB, Harper PA, Wong JM, et al. Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 2001;10:839-53.
48. Cosma G, Crofts F, Taioli E, et al. Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 1993;40:309-16.
49. Crofts F, Taioli E, Trachman J, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994;15:2961-3.
50. Kiyohara C, Hirohata T, Inutsuka S. The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 1996;87:18-24.
51. Rojas M, Alexandrov K, Cascorbi I, et al. High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM1*0/*0 genotypes. Pharmacogenetics 1998;8:109-18.
52. Mooney LA, Bell DA, Santella RM, et al. Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis 1997;18:503-9.
53. Persson I, Johansson I, Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 1997;231:227-30.
54. Zhang ZY, Fasco MJ, Huang L, et al. Characterization of purified human recombinant cytochrome P4501A1-462 and -Val462: assessment of a role for the rare allele in Carcinogenesis. Cancer Res 1996;56:3926-33.
55. Schwarz D, Kisselev P, Cascorbi I, et al. Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. Carcinogenesis 2001;22:453-9.
56. Nerurkar PV, Okinaka L, Aoki C, et al. CYP1A1, GSTM1, and GSTP1 genetic polymorphisms and urinary 1-hydroxypyrene excretion in non-occupationally exposed individuals. Cancer Epidemiol Biomarkers Prev 2000;9:1119-22.
57. London SJ, Yuan JM, Coetzee GA, et al. CYP1A1 I462V genetic polymorphism and lung cancer risk in a cohort of men in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2000;9:987-91.
58. Chen S, Xue K, Xu L, et al. Polymorphisms of the CYP1A1 and GSTM1 genes in relation to individual susceptibility to lung carcinoma in Chinese population. Mutat Res 2001;458:41-7.
59. Song N, Tan W, Xing D, et al. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis 2001;22:11-6.
60. Yang XR, Wacholder S, Xu Z, et al. CYP1A1 and GSTM1 polymorphisms in relation to lung cancer risk in Chinese women. Cancer Lett 2004;214:197-204.
61. Ng DP, Tan KW, Zhao B, et al. CYP1A1 polymorphisms and risk of lung cancer in non-smoking Chinese women: influence of environmental tobacco smoke exposure and GSTM1/T1 genetic variation. Cancer Causes Control 2005;16:399-405.
62. Shimada T, Watanabe J, Kawajiri K, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999;20:1607-13.
63. Mammen JS, Pittman GS, Li Y, et al. Single amino acid mutations, but not common polymorphisms, decrease the activity of CYP1B1 against (-)benzo[a]pyrene-7R-trans-7,8-dihydrodiol. Carcinogenesis 2003;24:1247-55.
64. Aklillu E, Ovrebo S, Botnen IV, et al. Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene. Cancer Res 2005;65:5105-11.
65. Bandiera S, Weidlich S, Harth V, et al. Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol 2005;67:435-43.
66. Watanabe J, Shimada T, Gillam EM, et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 2000;10:25-33.
67. Sorensen M, Autrup H, Tjonneland A, et al. Genetic polymorphisms in CYP1B1, GSTA1, NQO1, and NAT2 and the risk of lung cancer. Cancer Lett 2005;221:185-90.
68. Wenzlaff AS, Cote ML, Bock CH, et al. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 2005;26:2207-12.
69. Stucker I, Hirvonen A, de Waziers I, et al. Genetic polymorphisms of glutathione S-transferases as modulators of lung cancer susceptibility. Carcinogenesis 2002;23:1475-81.
70. Wang Y, Spitz MR, Schabath MB, et al. Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. Lung Cancer 2003;40:25-32.
71. Schneider J, Bernges U, Philipp M, et al. GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking. Cancer Lett 2004;208:65-74.
72. Cote ML, Kardia SL, Wenzlaff AS, et al. Combinations of glutathione S-transferase genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study. Carcinogenesis 2005;26:811-9.
73. Lewis SJ, Cherry NM, Niven RM, et al. GSTM1, GSTT1, and GSTP1 polymorphisms and lung cancer risk. Cancer Lett 2002;180:165-71.
74. Nazar-Stewart V, Vaughan TL, Stapleton P, et al. A population-based study of glutathione S-transferase M1, T1, and P1 genotypes and risk for lung cancer. Lung Cancer 2003;40:247-58.
75. Wang J, Deng Y, Cheng J, et al. GST genetic polymorphisms and lung adenocarcinoma susceptibility in a Chinese population. Cancer Lett 2003;201:185-93.
76. Skuladottir H, Autrup H, Autrup J, et al. Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years. A pooled study of lung cancer patients in Denmark and Norway. Lung Cancer 2005;48:187-99.
77. Lodovici M, Luceri C, Guglielmi F, et al. Benzo(a)pyrene diolepoxide (BPDE)-DNA adduct levels in leukocytes of smokers in relation to polymorphism of CYP1A1, GSTM1, GSTP1, GSTT1, and mEH. Cancer Epidemiol Biomarkers Prev 2004;13:1342-8.